- AU$8.58bn
- AU$8.60bn
- AU$2.35bn
Morningstar positive as Cochlear's acquisition of Oticon approved
Brief: Australia's ACCC Says It Will Not Oppose Revised Cochlear, Oticon Transaction
Macquarie says CSL, Resmed most preferred among Australian healthcare firms
Analysts hike PT on Australia's Cochlear on strong earnings, fundamentals
Australia's Cochlear declines after pausing share buyback
Australian health stocks drop most in 4 months; CSL falls after drug trial fails
Australian shares post first weekly fall in three as rate-hike bets back in focus
Australian shares post first weekly fall in three as rate-hike bets back in focus
Australia's Cochlear extends gains to hit record high
Brief: Cochlear Upgrades FY24 Earnings Guidance
Australia's Cochlear set for best day since mid-Aug on FY24 profit upgrade
Australia's Cochlear set for best day since mid-Aug on FY24 profit upgrade
Cochlear plunges as UBS asks investors to 'sell' over potential Moderna vaccine
Australian healthcare stocks on track to end 2023 higher
Growth in focus as macro questions linger on EU Consumer MedTech - Bernstein
Brief: UK's CMA Says On 24 August 2023 Accepted Final Undertakings For Cochlear / Oticon Merger Inquiry
Morningstar raises fair value estimate on medical device firm Cochlear
Australia's Cochlear hits 3-month high on strong annual earnings
Australia's Cochlear jumps on upbeat results, outlook